Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis - Wikidata - wikimedia - TriplyDB

Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis

Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis

http://www.wikidata.org/entity/Q35025556

about

Cellular targeting in autoimmunity Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions Imatinib enhances functional outcome after spinal cord injury Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?Dynamics and potential impact of the immune response to chronic myelogenous leukemia Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA/1J mice.Discoidin domain receptor 2 mediates collagen-induced activation of membrane-type 1 matrix metalloproteinase in human fibroblasts.c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.Tyrosine kinases in inflammatory dermatologic disease.JNK1 controls mast cell degranulation and IL-1{beta} production in inflammatory arthritis Development and experimental test of support vector machines virtual screening method for searching Src inhibitors from large compound libraries.Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.Intracellular signal pathways: potential for therapies.In vivo quantification of mouse autoimmune arthritis by PET/CT Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats.Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases.Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis Survivin is an essential mediator of arthritis interacting with urokinase signalling.Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ.Nilotinib protects the murine liver from ischemia/reperfusion injury.Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome.Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.Gait analysis in a murine model of collagen-induced arthritis.Delayed Imatinib Treatment for Acute Spinal Cord Injury: Functional Recovery and Serum Biomarkers Approaches for analyzing the roles of mast cells and their proteases in vivo.Developments in the synovial biology field 2006.Mast cell regulation of the immune response.Consumption of hydrolyzable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis.Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis Sunitinib enhances neuronal survival in vitro via NF-κB-mediated signaling and expression of cyclooxygenase-2 and inducible nitric oxide synthase.Molecular framework for response to imatinib mesylate in systemic sclerosis.Anti-inflammatory Agents: Present and Future Tibetan Medicated-Bath Therapy may Improve Adjuvant Arthritis in Rat Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

P2860

Q26824580-6E3EFDD4-CF73-491C-BA56-9B3744109377 Q28078946-5586F155-3461-462F-AA5C-F7482A06E81D Q28480537-18B26EBE-CFD9-4336-B19E-32ADB02361DD Q33314413-A7052CC4-1EC0-4948-9CC3-BD6820D872E5 Q33345245-A7ABB764-6BA2-43FB-AC04-59A762F0A70C Q33410688-4319443E-7088-4D77-8745-CBA4D862F7D4 Q33586567-724138A1-C4AA-43AD-B0EC-463D14C7C5E5 Q33873745-49130B16-0F9F-4895-946A-1C889436D8C2 Q34166503-683E1CA2-7C2F-48E3-8291-0C8B12A6BC6B Q34438110-AB3CD840-F33B-4530-A3DF-2BB2C7A1FD75 Q34485998-B81BB031-261A-4F5D-A339-BCA036B25201 Q34486262-311F80CB-82DE-44ED-A42B-C9445494870B Q34551138-D4806D67-5693-4780-93D9-D553690C5004 Q34777280-6FD7AF5A-C482-426A-9B7E-689C7E8EA74B Q35014605-FF348793-BA17-43AC-A5FF-3EEFED9DCF59 Q35161761-A332B3E0-85A5-4C4D-A477-9455AF74B778 Q35187101-34C849DA-ECBA-431D-8A33-67FE8FE87F50 Q35566387-22CF981A-8593-4513-B41D-0316BF93FFAC Q35577914-E22C8B13-4605-4679-ABAB-3A6AB1F84483 Q35893385-D7ECFFD1-44F2-4E6E-A60F-626834DA2C9B Q36110355-6E9F8C0C-8DF5-4ECC-BD5D-B32BDFEAEDA3 Q36162943-082BF3E1-4E06-46C9-953E-483C9E6D6485 Q36219461-F39B8086-0C6E-4199-9F87-2FB68304CB41 Q36306823-5F48134A-B310-4939-BA95-09B43080DAE5 Q36407079-B6081BAF-092F-411C-94A1-A115D017AA1A Q36463168-E9F3A35C-1E92-4E22-9F7E-72DB9332B982 Q36465487-CC2735F3-8851-4100-A8AA-3988542B0075 Q36576063-6F0CD6E4-3326-4282-BE31-B861E52BADD2 Q36630944-57349AD4-9C5B-4D4D-8ADB-08B3E55331AF Q36794899-59EC5697-49C7-4139-A79D-FF7ABFB96464 Q36834357-7172D7C1-973A-44D2-98AB-384187056CF8 Q36961298-90C1DACF-C08E-4BDE-B36E-A5781E50A124 Q36999931-27576B4D-0CC2-4E9C-84B7-22D32ADF88E3 Q37031073-7DD04801-4F8F-4E09-A63C-C88304299424 Q37042174-CDF9EB06-3EE8-42BA-9E14-63EEA5B85CF6 Q37053448-79CFA5B4-5103-4F1C-A720-75A8139F6E8A Q37088947-825280AE-4B70-4293-A7F8-5CBBE0268D9E Q37118156-819BEFD2-F5BC-4C6B-BB72-8DBD932B0D58 Q37202871-B359A612-5C02-49CD-AD6D-1D468F5D182D Q37270882-BD5F24E7-A7DE-4E9D-AE52-70BC29082C20

P2860

Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis

http://www.wikidata.org/entity/Q35025556

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Selective tyrosine kinase inhi ...... atment of autoimmune arthritis

@ast

Selective tyrosine kinase inhi ...... atment of autoimmune arthritis

@en

type

label

Selective tyrosine kinase inhi ...... atment of autoimmune arthritis

@ast

Selective tyrosine kinase inhi ...... atment of autoimmune arthritis

@en

prefLabel

Selective tyrosine kinase inhi ...... atment of autoimmune arthritis

@ast

Selective tyrosine kinase inhi ...... atment of autoimmune arthritis

@en

P1433

Q35025556-F4C4B13A-5BFC-4FA5-A93B-4A44428D8307

P1476

Q35025556-C208B05F-E7C7-4F69-88D0-FA5BB0EAF926

P2093

Q35025556-235B5BA9-37DE-4BA2-9F15-50DA74EFF44A

Q35025556-2C5280BA-2279-40CD-8C5D-7AACC82B299E

Q35025556-3B58A612-C772-4253-88D9-D6CF0CB25CA3

Q35025556-532C2DBE-BE1D-4190-9B8B-462556E953D1

Q35025556-5C04C69E-18F8-4D23-B32A-F5421B7D61B7

Q35025556-6D991686-3009-4270-9B23-FC4B5674D02B

Q35025556-76AC21E3-EDB6-4259-B4BF-34778272C659

Q35025556-8043669F-F269-479C-BD5D-0F356B7A6413

Q35025556-83879696-E499-4789-82C4-0EDBA51A203D

Q35025556-8C302308-1978-4178-A2A1-D7BEE8E7219F

P2860

Q35025556-0077D285-F130-4B6A-9479-84505E22DA38

Q35025556-0B9666F5-33C0-4694-B3F0-8BB766657A53

Q35025556-1365EA87-DAB4-4E0A-AE49-11CEDE04E20B

Q35025556-1549FF57-BC49-4DC2-B720-0C3EA2B8A959

Q35025556-15E33EFE-2AD2-4B8E-BF0E-5ED786B91A06

Q35025556-1D89DC2D-0D6E-4B85-8B19-6603D089BA8B

Q35025556-1F599B06-52B7-44C6-9466-0007C9BAD0C3

Q35025556-21981BC1-B505-42BB-90DC-48091830DD99

Q35025556-284B7CE0-51BF-421D-9CFC-F57500D21E0A

Q35025556-297431F8-54E0-4FFC-AE0C-6D35B357C35C

P304

Q35025556-0BE9E503-EB20-4049-83D3-77092DF1B176

P31

Q35025556-2EC2E2B0-2998-4EF3-894E-323EA3E26D1D

P356

Q35025556-61BE17A3-312A-4171-BB3F-8EEFB2215223

P407

Q35025556-44A9A950-FEA0-434E-A410-8AB7C772696D

P433

Q35025556-97910753-6F74-4B52-AD0C-5B3379D4B012

P478

Q35025556-0783E2C6-88DE-44BE-BED3-41DB7D4BFB58

P577

Q35025556-36219DD8-96BD-4E6A-BF38-27D1D71BC734

P5875

Q35025556-8134D095-A69D-4D96-A602-833D421BB91B

P698

Q35025556-F8895E4F-0B8E-49CC-87FA-24C4525BF28C

P932

Q35025556-3B8EE17C-6B17-4B20-B86E-B0FFF0D7B703

P356

P1433

Journal of Clinical Investigation

P1476

Selective tyrosine kinase inhi ...... atment of autoimmune arthritis

@en

P2093

Anna Chang

http://www.w3.org/2001/XMLSchema#string

Beren H Tomooka

http://www.w3.org/2001/XMLSchema#string

David M Lee

http://www.w3.org/2001/XMLSchema#string

Fiona M Thomas

http://www.w3.org/2001/XMLSchema#string

Jason J Song

http://www.w3.org/2001/XMLSchema#string

John P Higgins

http://www.w3.org/2001/XMLSchema#string

Lawrence Steinman

http://www.w3.org/2001/XMLSchema#string

Mark C Genovese

http://www.w3.org/2001/XMLSchema#string

Orr Sharpe

http://www.w3.org/2001/XMLSchema#string

Paul J Utz

http://www.w3.org/2001/XMLSchema#string

P2860

The c-Abl tyrosine kinase is regulated downstream of the B cell antigen receptor and interacts with CD19

Significance analysis of microarrays applied to the ionizing radiation response

Cluster analysis and display of genome-wide expression patterns

Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis

Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion

Mast cells in inflammatory arthritis

Macrophages in rheumatoid arthritis

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

P304

2633-2642

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI28546

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6813280

http://www.w3.org/2001/XMLSchema#string

P698

16981009

http://www.w3.org/2001/XMLSchema#string

P932

1564430

http://www.w3.org/2001/XMLSchema#string